Onyvax's Immunotherapy Shows Promise in Delaying Prostate Cancer Progression

Strategic Insights -

Clinical trials for Onyvax-P, a new immunotherapy, have revealed encouraging results in delaying the progression of hormone-resistant prostate cancer (HRPC) in patients. A paper published in Clinical Cancer Research confirms that the treatment, administered to patients with rising PSA levels, demonstrated a statistically significant decrease in PSA velocity and a longer median time to disease progression. This breakthrough could offer a novel treatment option for men with HRPC, a stage of prostate cancer that is often resistant to traditional therapies.

Key Takeaways:

  • 42% of patients treated with Onyvax-P showed statistically significant, prolonged decreases in their PSA velocity (PSAV) without experiencing significant toxicity.
  • The vaccination approach resulted in an extended median time to disease progression (TTP) of 58 weeks, a significant improvement over the historical experience of 26-29 weeks.
  • Artificial Neural Network (ANN) analysis was used to show that certain cytokine profiles could predict clinical outcome with a high degree of accuracy, potentially providing a new tool in managing HRPC patients.
  • Onyvax-P has been confirmed to delay the progression of hormone-resistant prostate cancer (HRPC) in patients.
  • The treatment makes Onyvax a compelling option for men with HRPC, a common cancer in the United States.
  • The Atlas of Clinical Urology reports that HRPC patients develop asymptomatic bone metastases 26 weeks after a rising PSA, symptomatic bone metastases 17 weeks after that, followed by death 52 weeks later.

Statistics:

  • 42% of patients treated with Onyvax-P showed prolonged decreases in PSA velocity.
  • The median time to disease progression (TTP) was extended to 58 weeks.
  • Historical experience suggests a median TTP of 26-29 weeks.
  • ANN analysis predicted clinical outcome with up to 100% accuracy.
  • HRPC patients develop asymptomatic bone metastases 26 weeks after a rising PSA.
  • Symptomatic bone metastases occur 17 weeks after asymptomatic metastases.
  • Death occurs 52 weeks after symptomatic metastases.
  • Onyvax is a biotechnology company developing novel cancer therapies.

Sources:

  • Clinical Cancer Research, vol. 11, 4469-4478
  • Atlas of Clinical Urology